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joints (P=0.004). OC injured SF C2C concentrations were posi-
tively correlated with radiographic scores (R=0.43; P=0.03) and
arthroscopic scores (R=0.52; P=0.03). Arthroscopic scores were
positively correlated with radiographic scores (R=0.51; P=0.04).
SF C2C concentrations ≥ 64 pmol/mL for MCP/MTP joints and ≥
75 pmol/mL for carpal joints were arbitrarily chosen to determine
predictive value for discriminating OC injured horses from rested
or exercised horses. This yielded a positive predictive value of
73% and a negative predictive value of 94% for the MCP/TP
joints, and positive predictive value of 79% and negative predic-
tive value of 95% for the carpus.
Conclusions: OC injury caused a signiﬁcant increase in SF
C2C concentrations in carpal and MCP/MTP joints compared
to rested and exercised horses. SF C2C concentrations were
correlated to severity of joint injury. Based on these ﬁndings, SF
C2C analysis may be useful for evaluation of joint injury.
Acknowledgment: Study supported in part by the University of
Florida Equine Soundness Program.
105
FOLLOW-UP OF COLL2-1, COLL2-1NO2 AND
MYELOPEROXYDASE SERUM LEVELS IN MARATHON
RUNNERS
M. Deberg1, A. Labasse1, C. Sanchez1, A. Bosseloir2,
Y. Henrotin1
1University of Liège, Liège, Belgium; 2Zentech, Liège, Belgium
Purpose: To determine the inﬂuence of marathon on the serum
levels of two markers of cartilage degradation, Coll2-1, a peptide
of type II collagen triple helix, and its nitrated form, Coll2-1NO2,
and of a marker of neutrophils activation, the myeloperoxidase
(MPO).
Methods: Coll2-1, Coll2-1NO2 and MPO were measured by
speciﬁc immunoassays in 66 marathon runners without joint
pain and aged in mean of 47 (min: 31 - max: 59) years. Sera
were taken before and after the marathon. All the subjects were
submitted to a questionnaire concerning their physical activity
(i.e. training or best performance) and their life style (i.e; diet).
The total running distance was 42 km. Their performance in the
marathon was ranged from 149 to 270 min.
Results: Before the marathon, the Coll2-1 and Coll2-1NO2 val-
ues were not affected by age, body mass index, sex and per-
formance [Coll2-1 median: 90.66 (28.77-234.68) nM and Coll2-
1NO2 median: 0.16 (0.05-0.71) nM], while MPO levels were
higher in female [median: 41.3 (29.90-96.50) ng/ml] than in
male [median: 33.00 (15.60-84.60) ng/ml] (p<0.05). After the
marathon, Coll2-1 levels were slightly decreased [median: 76.63
(28.89-185.06) nM], Coll2-1NO2 levels were unmodiﬁed [median:
0.15 (0.05-0.61) nM] and MPO levels were doubled [median:
71.80 (31.50-172.10) ng/ml] compared to the pre-marathon val-
ues [MPO median: 34.20 (15.60-96.50) ng/ml] (p<0.001). The
variation of MPO during the marathon was negatively correlated
with the training time per week (r=-0.36; p=0.0045). Before the
marathon, there was no correlation between the different biolog-
ical markers (Coll2-1, Coll2-1NO2 and MPO).
Conclusions: Coll2-1 and Coll2-1NO2 serum levels were not
modiﬁed by marathon, suggesting that, at least at short-term,
this intensive physical activity does not signiﬁcantly modiﬁed
cartilage metabolism. Interestingly, serum MPO levels were in-
creased after the marathon and training reduced this elevation.
These results suggest that neutrophils were activated during the
marathon and that training reduces neutrophils activation during
the marathon.
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Purpose: Aggrecan proteolysis is an early key event in arthritis.
Aggrecanases cleave the interglobular domain of aggrecan re-
leasing N-terminal ARGS fragments, and the chondroitin sulfate
rich domain releasing C-terminal G3 domain fragments. Several
reports suggest a role for more than one ADAMTS activity and
possibly other proteases in the release of aggrecan fragments
from joint cartilage. Differences between animal models and hu-
man disease, and differences between human joint diseases
and disease stages suggest a role for a method to map in detail
aggrecan proteolytic fragments in multiple samples. We have
developed a quantitative Western blot method for analysis of
aggrecan fragment patterns in synovial ﬂuids (SF) from patients
with different joint diseases.
Methods: Dissociative CsCl gradient centrifugation was used
for sample preparation from SF of 5 knee-healthy subjects (ref-
erence) and 27 patients with 4 different knee joint diseases.
Aggrecan fragments (D1-fractions) separated by SDS-PAGE and
transferred to PVDF membranes were screened, using a digi-
tal luminescence imager, with an ARGS neo-epitope antibody
or an antibody recognizing the G3-domain. ARGS-standards
were generated by complete aggrecanase digestion of intact hu-
man aggrecan. Quantiﬁcation was by co-running either ARGS-
standards or a control sample (in G3 quantiﬁcation) on each
SDS-gel. Results were compared and expressed as mol (ARGS)
or relative AU (G3) per mg glycosaminoglycan (GAG) determined
by Alcian Blue precipitation.
Results: GAG recovery in D1-fractions was >75%, and West-
ern blot CVs between experiments for anti-ARGS and anti-G3
were 19% and 28%. Total ARGS fragment quantity in SF sam-
ples by Western blot correlated well with ARGS-ELISA (R2=0.87,
n=19), while the correlation between ARGS and GAG content
was only moderate (R2=0.31, n=31). SFs contained two major
ARGS-bands, ARGS-SELE and ARGS-GVED, and three major
G3-bands (GRGT-G3, GLGS-G3 and AGEG-G3) as a result of
aggrecanase proteolysis. Median values of total ARGS fragments
in the diagnostic groups were signiﬁcantly higher in the acute
arthritis and acute injury groups compared to the reference,
and these SF samples contained the highest total ARGS values
per mg GAG (Table 1; *P<0.05; **P<0.01 compared to refer-
ence). The differential between reference and disease groups
was greatest for the ARGS-SELE fragment. Median values of
total G3 per mg GAG were signiﬁcantly lower in the acute arthri-
tis and osteoarthritis groups than in the reference. The ratios of
total-ARGS to total-G3 fragments varied markedly between the
diagnostic groups.
Table 1. Western blot analysis in diagnostic groups. Median values normalized
to reference
Group n ARGS- ARGS- Total Total Total
SELE GVED ARGS G3 ARGS/G3
Reference 5 1 1 1 1 1
Acute arthritis 8 25** 10.1** 10.7* 0.5* 22.3*
Acute injury 9 20.2** 10.2** 10* 0.6 9.5**
Chronic injury 5 4.2 2.2 2.1 1.2 0.9
Osteoarthritis 5 8.4 2.9 3.4 0.3* 2.6
Conclusions: We have developed a quantitative Western blot
method for aggrecan fragment screening of synovial ﬂuids. It
provides reliable results as judged by relatively low CV and good
correlation between Western and ELISA methods. Anti-ARGS
